This characteristic makes it a challenging ingredient to incorporate into palatable forms
Chinas Oral GLP-1 market is expanding rapidly in 2025 due to the countrys rising diabetes and obesity rates, with nearly 148 million diabetic adults and over 60% of the population overweight or obese, creating strong demand for effective glucose-lowering and weight-management therapies
Semaglutide : Another synthetic GLP-1 agonist, semaglutide has a longer half-life, providing extended control over blood sugar levels and appetite suppression
This reduction in brain loss went along with 18% slower decline in cognitive function in a year
Your complete medical history should be reviewed, including: Cardiovascular conditions (hypertension, arrhythmias, heart disease) History of eating disorders or significant weight fluctuations Mental health conditions (anxiety, depression, bipolar disorder) Gastrointestinal disorders (gastroparesis, inflammatory bowel disease) Diabetes and current glucose-lowering medications Any history of substance misuse Gallbladder disease or pancreatitis Pregnancy and contraception must be discussed
Microbiol Spectr 11:e0520922 OToole GA (2011) Microtiter dish biofilm formation assay